KSX 0.00% 1.5¢ karmelsonix ltd

ann out, page-5

  1. 231 Posts.
    This is news that the market would like to see... it is a bit strange that it is note marked as price sensitive as this IS a major milestone - the beginning of sales...
    30th May 2008: The Directors of KarmelSonix Ltd (ASX : KSX) are pleased to announce that the
    first sale of multiple units of the PulmoTrack® have been completed in Australia. The sale of the
    units to a major private sector medical group represents a significant milestone in the commercial
    rollout of the Company’s products. It also represents an important step in the initial transition
    from an R & D company to one focussing on the full commercialisation of the Company’s non-
    invasive asthma monitoring and management tools.
    Training for the PulmoTrack® units will be provided by KSX to the group’s personnel which will
    enable testing of asthma patients to commence in July. This initial rollout represents an important
    step in the adoption of this new approach to the monitoring and management of asthma.
    Commenting on these initial sales, KSX Chairman, Mr Peter Marks said, “the sales to a substantial
    private sector medical group is an important achievement in the commercial rollout of the
    PulmoTrack® and augurs very well for further penetration of the market with this and subsequent
    products over the coming months, and beyond.”
    Following receipt of TGA approval in Australia in March 2008, and with preliminary marketing
    activities underway since then, there has been substantial interest within the hospital and primary
    care sectors in the capabilities of the PulmoTrack®, particularly with its unique ability to assess
    asthma and wheeze without patient effort or co-operation.
    Backing up the release of the PulmoTrack® will be the upcoming launch of the Nocturnal Asthma
    Monitor and the WHolter – the 24 hour asthma monitor. Both products will complement the
    existing features of the PulmoTrack®. KSX recently received further highly positive feedback on
    the PulmoTrack® at the American Thoracic Society (ATS) Conference held in Philadelphia where
    doctors, clinicians and others were highly enthusiastic about the Company’s products and their
    entry into a variety of clinical settings.

 
watchlist Created with Sketch. Add KSX (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.